News & Updates

Use of oral bisphosphonate or denosumab does not appear to increase the risk of cardiovascular events (CVEs), namely acute myocardial infarction, unstable angina, cerebrovascular accident, and transient ischemic attack, in persons with incident fracture, a study has shown.

Perampanel appears to be effective and have good tolerability in patients with idiopathic generalized epilepsy treated in everyday clinical practice settings, as shown in a study.

High-risk outpatients with early-onset COVID-19 who are treated with oral fluvoxamine plus inhaled budesonide have a reduced incidence of severe disease that warrants advanced care, reveals a study.

An emulation of a randomized target trial suggests that molnupiravir may reduce hospital admission or death in adults who have tested positive for COVID-19 during the predominance of Omicron who were at high risk of progression to severe disease.

Use of nonvitamin K antagonist oral anticoagulants (NOACs) helps prevent thromboembolic events in Asian patients with atrial fibrillation (AF), with fewer bleeding events relative to warfarin therapy, according to the results of a study presented at the recent EHRA 2023.